IngredientsEudragit® is not, strictly speaking, a botanical ingredient or a naturally derived dietary supplement constituent. It is a fully synthetic polymer excipient used extensively in the pharmaceutical and nutraceutical industries as a coating, encapsulation, or matrix-forming material. It has no traditional herbal or nutritional identity and no history of traditional medicinal use in the sense that plant-based supplements do. Its significance in the dietary supplement and nutraceutical context arises entirely from its function as a delivery technology: it is applied as a coating or encapsulation agent to tablets, capsules, pellets, and microparticles containing active supplement ingredients—vitamins, minerals, probiotics, botanical extracts, and other bioactives—in order to control where, when, and how those actives are released in the gastrointestinal (GI) tract. Any article purporting to discuss Eudragit as a "natural ingredient" therefore addresses it in its proper role as an excipient or formulation polymer, and all claims below are presented accordingly, with a rigorous delineation between what the polymer itself is, what the science shows it does as an excipient, and where the evidence stands.
Eudragit® was a trademark of Rohm GmbH & Co. KG in Darmstadt, Germany, first marketed in 1953. The name was derived from the Greek word "Εύ" (meaning "good") and the German word "dragieren" (meaning "sugar coating"), combined to indicate a high-quality coating material. The brand is today owned and manufactured by Evonik Industries AG (Essen, Germany), the successor entity to Röhm & Haas GmbH.
EUDRAGIT® is the trade name for copolymers derived from esters of acrylic and methacrylic acid, whose properties are determined by functional groups. The individual EUDRAGIT® grades differ in their proportion of neutral, alkaline, or acid groups and thus in terms of physicochemical properties.
Eudragits are synthetic polymers produced by polymerization of acrylic acid as well as methacrylic acid or their esters, such as dimethylaminoethyl ester or butyl ester. Eudragit, synthesized by radical polymerization, is used for enteric coating, precise temporal release, and targeting the entire gastrointestinal system.
It is an extensive collection of anionic, cationic, or neutral copolymers derived from methacrylic acid and methacrylic or acrylic esters, as well as their derivatives. The polymers are referred to generically as poly(meth)acrylates or polymethacrylates, and individual grades are listed in international pharmacopeias under designations such as "Methacrylic Acid Copolymer, Type A, B, or C" and "Ammonio Methacrylate Copolymer, Type A or B."
Eudragit is introduced in USP/NF, BP (British Pharmacopoeia), Ph.Eur. (European Pharmacopoeia), and the Handbook of Pharmaceutical Excipients. Acid-insoluble polymer specifications are detailed in the United States Pharmacopoeia and in various monographs. This multi-pharmacopeial recognition establishes Eudragit grades as globally recognized excipient standards, not proprietary trade secrets—regulators in Europe, North America, Japan, and beyond accept these materials on the basis of codified quality specifications.
Many different grades of Eudragit polymer are usually available as granules, dry powder, organic solvent, and aqueous dispersion forms. EUDRAGIT® polymers are available in a wide range of different concentrations and physical forms, including aqueous solutions, aqueous dispersion, organic solutions, and solid substances.
Until the 1950s, all oral medications, even the most modern, had one big disadvantage: it was not possible to control the time or release location of the active pharmaceutical ingredient. The development of Eudragit by Rohm & Haas GmbH in Darmstadt was the solution to this problem.
Until the 1940s, all orally administered medicines suffered from a significant disadvantage: the release of active ingredients in the body at the right time and in the right place could not be precisely controlled. This only changed with the development of EUDRAGIT® at Röhm & Haas, now the Evonik site in Darmstadt. At the beginning of the 1950s, scientists came up with the idea of coating tablets with a plastic and thus regulating the release of the active ingredients. In 1953, the first four prototypes were developed and launched in 1954 under the EUDRAGIT® brand.
The first drug coatings developed in 1953 were alkaline-soluble and therefore resistant to stomach acids. The active substances were therefore not released in the stomach but in the intestine, where they were to be activated.
Seven decades ago, scientists in Darmstadt, Germany, made a significant discovery that was to have a profound impact on the pharmaceutical industry. They found that polymers derived from esters of acrylic and methacrylic acid could create highly effective coatings for tablets. EUDRAGIT®, introduced 70 years ago, expanded the possibilities for drug developers and manufacturers with innovative functionalities, such as gastro-resistance, moisture protection, and taste and odor masking.
Eudragit L-30D was introduced in 1972. Subsequent decades saw the development of further grades to address increasingly specific release profiles across all segments of the GI tract.
There is no traditional medicinal or ethnobotanical history of use for Eudragit. The polymer family was created in the mid-twentieth century by industrial chemists and has never been used in folk or traditional medicine. Its entire history is one of pharmaceutical and nutraceutical excipient science.
The ratio of methacrylic acid to its methacrylate-based monomers used in the polymerization reaction defines the final product's characteristics and consequently its potential range of applications. Grades are divided into three broad functional categories based on their ionic character and solubility behavior:
The primary functional mechanism of anionic Eudragit grades is their pH-dependent ionization behavior. The protection of Eudragit S100 on encapsulated substances is attributed to their active carboxylic groups. In a slightly acidic environment (a pH range of 5.0–7.0), these carboxylic groups are converted into carboxylate and form a water-insoluble film, which can resist gastric acid and block the penetration of water vapor.
Their operation is based on carboxyl groups (-COOH). In the corrosive, acidic pH of the stomach (1.0–3.0), these groups remain protonated (non-ionized). When the drug enters the duodenum and the pH rises above a specific threshold (the polymer's pKa value), a hydrogen ion is cleaved (deprotonated to the -COO⁻ anion). In a fraction of a second, the polymer acquires an electrical charge, becomes extremely hydrophilic, absorbs water, and releases the drug.
This allows precise spatial targeting: Eudragit L 100-55 and L 30 D-55 release the drug in the duodenum (pH > 5.5), Eudragit L 100 in the jejunum (pH > 6.0), and Eudragit S 100 and FS 30 D in the ileum and colon (pH > 7.0).
For the RL, RS, NE, and NM series, the release mechanism is not dissolution but swelling-controlled diffusion. Due to the amorphous Eudragit structure, it exhibits prolonged release. These grades form water-insoluble matrices that swell at any pH, allowing the active ingredient to diffuse out at a rate governed by the polymer's permeability and the concentration gradient across the coating.
pH-responsive Eudragit® polymers offer clinically validated advantages: Eudragit® L100-coated systems demonstrate near-quantitative (98.2 ± 1.4%) gastric protection through molecular gastight sealing (≤0.4 nm pore size at pH < 5), followed by rapid dissolution (T90 = 8.7 min) at intestinal pH to enable localized probiotic release.
Eudragit® FS30D is a pH-dependent polymer that dissolves in an environment above pH 7.0, while Eudragit® RS100 is a time-dependent, controlled-release polymer having low permeability. Combining these two polymers effectively minimized premature drug release in the upper GI tract and achieved sustained drug release throughout the colon.
A combination of Eudragit® S and L compounds (e.g., Eudragit® L/S 100) effects a controlled release of the active substances at pH > 6.4, which occurs in the terminal ileum.
Eudragit polymers serve no pharmacologically active function themselves. Their role in supplements is exclusively formulation-based: enabling the delivery of active ingredients to the most physiologically appropriate site in the GI tract, protecting actives from premature degradation, masking unpleasant tastes or odors, and extending or modulating the duration of release.
EUDRAGIT® polymers can provide the following possibilities for controlled drug release: gastrointestinal tract targeting (gastroresistance, release in the colon), protective coatings (taste and odor masking, protection against moisture), and delayed drug release (sustained-release formulations).
Eudragit L 30 D-55 is used as an enteric coating film former for solid-dosage forms. The coating is resistant to gastric juice but dissolves readily at above pH 5.5. This property makes Eudragit L grades the standard enteric coating material for acid-sensitive supplements, including omega-3 fish oil capsules, probiotic products, and certain enzyme preparations.
Eudragit polymers have been extensively investigated as enteric coatings for live probiotic bacteria, where the primary challenge is survival through gastric acid before reaching the intestine.
Methacrylate copolymers such as Eudragit® provide reliable enteric protection by remaining intact under gastric acidity and dissolving at intestinal pH, enabling site-specific delivery of Lactobacilli and Bifidobacteria. For example, enteric-coated capsules with Eudragit L100–55 did not disintegrate in simulated gastric fluid and were designed for release in the intestine, confirming the suitability of methacrylate coatings for oral probiotic delivery.
Microencapsulation with Eudragit S100 has likewise maintained viable probiotic counts above 6 log CFU mL−1 after simulated gastric exposure, evidencing gastric protection and downstream release.
The enteric microparticles remained unaltered under simulated gastric conditions and released the contained viable microbial cargo under simulated intestinal conditions. Buoyancies of 90.2% for Eudragit microparticles and long-term stability (5 months) for the encapsulated microorganisms were found. Cytotoxicity of the microparticles formulated with both polymers was evaluated (0.5–20 mg/mL) on Caco-2 cells, showing high cytocompatibility.
The increased pH in the intestine induced the hydrophobic Eudragit to become hydrophilic, subsequently releasing the bacteria to targeted sites. Eudragit coating could protect dried live cells from the acidic stomachic environment and guarantee the rapid release of cells in the intestine.
The evidence for Eudragit's protective role in probiotic delivery is primarily from in vitro and animal studies modeling gastric conditions. Clinical evidence directly comparing Eudragit-coated versus non-Eudragit-coated probiotic supplements in human trials for specific health outcomes is limited; the polymer is generally a vehicle for the active (probiotic organisms) whose clinical evidence must be evaluated independently.
pH-responsive delivery platforms employ polymers that remain stable in the acidic gastric environment but undergo solubilization or swelling in the neutral to slightly alkaline conditions of the small intestine and colon (pH ~6.5–7.5), enabling oral delivery of nutraceuticals that bypass premature degradation. Methacrylate-based polymers such as Eudragit S100, which dissolves above pH 7, have been widely used to protect polyphenols and probiotics until they reach the colon.
In vitro dissolution studies revealed that Eudragit®-S100-coated aminated nanomaterials prevented the burst release of the loaded catechin in the acidic environment, with approximately 90% of the catechin only being released at colonic pH (pH > 7) with a supercase II transport mechanism.
Research involving Eudragit-coated nutraceuticals (e.g., polyphenols, curcumin, catechins) in the context of colonic delivery has largely been conducted at the in vitro or preclinical level. Translation to controlled human trials with clinical endpoints is an active area of research, but evidence at the human level specific to Eudragit-coated nutraceuticals remains early-stage or absent in most cases.
A key rationale for Eudragit use in supplements is to protect bioactive compounds—particularly those vulnerable to gastric acid, digestive enzymes, or degradation in the upper GI tract—so that more reaches the intended site of absorption. The polymer-based nanoparticulate drug delivery systems have been known to be an efficient approach to enhance drug absorption, improve bioavailability, targeting of therapeutic agents to the colon, and reduce toxicity. This principle applies in the nutraceutical context for ingredients such as omega-3 fatty acids, curcumin, quercetin, and live bacteria.
Quercetin is a natural dietary compound known for its potential to prevent chronic diseases. However, the translation of this success to humans is hindered due to quercetin's poor oral bioavailability, attributed to its extremely low water solubility and permeability. Eudragit-polymer complexes have been studied to address this limitation, though clinical evidence in humans for the bioavailability benefit of Eudragit-quercetin formulations specifically is still at a preliminary stage.
Targeted ileo-colon delivery is a highly desirable approach for the local treatment of a variety of bowel diseases such as ulcerative colitis, Crohn's disease, and colon cancer. Additionally, the selective release in this area of sensitive compounds such as proteins and peptides can improve their systemic bioavailability. Eudragit FS 30 D and S 100 grades are specifically investigated for this application due to their dissolution threshold at colonic pH values.
Colon-specific drug delivery systems (CDDS) should be capable of protecting the drug in the stomach and in the small intestine, allowing drug release and absorption once the system reaches the colon. CDDS can possess several advantages, including reduction of drug payload and of the incidence of side effects, bypassing the liver first-pass metabolism, improving patient compliance, reducing gastric irritation caused by some drugs, and improving the local bioavailability of poorly absorbed drug molecules.
Research in this domain involving Eudragit as a carrier for anti-inflammatory agents or nutraceuticals with IBD relevance (e.g., budesonide, curcumin) is predominantly preclinical. Robust, randomized, placebo-controlled human clinical trials evaluating Eudragit-coated supplement formulations specifically for IBD management are limited.
Estimated daily intake of basic methacrylate copolymer from proposed uses in micronutrient delivery has been formally evaluated in GRAS dossier submissions. Eudragit E PO (the cationic grade) has been specifically evaluated in the context of coating micronutrients, offering taste and odor masking and protection against moisture and chemical interactions—relevant in multivitamin and mineral supplement formulations.
As an excipient, Eudragit itself does not exert pharmacological effects on body systems. The body systems listed below are those where Eudragit-coated or Eudragit-matrix formulations of active ingredients are under research or clinical use:
Eudragit is not consumed as a standalone supplement at a defined "dose" the way an active ingredient is. Rather, it is present as a coating or matrix material at levels that vary by formulation goal. The following are reported in the scientific literature:
It is essential to distinguish evidence concerning Eudragit's performance as an excipient (physicochemical, in vitro, and in vivo animal data demonstrating coating integrity, pH-responsive dissolution, and stability) from clinical evidence concerning health outcomes in humans taking Eudragit-formulated supplements. The former is well-established; the latter is almost always attributable to the active ingredient rather than to Eudragit itself.
Evidence strength: Strong for physicochemical performance; early-stage to moderate for nutraceutical applications.
Among pH-sensitive excipients, methacrylic acid copolymers (Eudragit® series) are the most extensively utilized. Their dissolution profiles are pH-dependent: Eudragit® L100 dissolves at pH 6.0, Eudragit® S100 at pH 7.0, Eudragit® L30D at pH 5.6, Eudragit® FS30D at pH 6.8, and Eudragit® L100-55 at pH 5.5.
The pH-dissolution profiles have been characterized in numerous peer-reviewed studies using USP dissolution apparatus and validated simulated gastric/intestinal fluids. This evidence base is robust and reproducible. Translation to human GI performance is supported by the pharmacopeial acceptance of enteric coating dissolution tests that model in vivo conditions.
Evidence strength: Moderate (in vitro/preclinical); limited human clinical data for Eudragit-specific formulations.
Eudragit is a class of anionic copolymers synthesized from acrylic or methacrylic acid and their ester monomers. Due to its exceptional pH-dependent dissolution properties, it is widely used as an enteric coating material.
In vitro studies using simulated gastric fluid (pH 1.2, 2 h) followed by simulated intestinal fluid (pH 6.8 or 7.4) consistently demonstrate that Eudragit-coated probiotic formulations maintain substantially higher viable bacterial counts than uncoated controls. Microencapsulation with Eudragit S100 has maintained viable probiotic counts above 6 log CFU mL−1 after simulated gastric exposure.
Whether this in vitro protection translates into superior clinical probiotic efficacy (e.g., better colonization rates, improved GI outcomes) in human trials has not been definitively demonstrated in controlled studies reviewed for this article. The probiotic clinical literature supports specific strains for specific conditions, but Eudragit coating specifically as the determinant variable in human outcomes has not been isolated.
Evidence strength: Preliminary (in vitro and animal data only for most compounds).
Multiple studies have used Eudragit polymers to formulate poorly bioavailable nutraceuticals such as curcumin, quercetin, resveratrol, and catechins. The consistent finding is improved in vitro dissolution at target pH conditions and, in animal models, improved bioavailability parameters compared to unformulated reference compounds.
In vitro tests reveal that under mildly acidic environments, Eudragit-coated curcumin and berberine hydrochloride nanoparticles exhibit a controlled and sustained release over an extended period. This slow and steady delivery effectively prolongs the drugs' therapeutic effect.
Human clinical trials specifically evaluating Eudragit-formulated polyphenols against unformulated controls are sparse in the reviewed literature. Most claims about bioavailability enhancement derive from preclinical models.
Evidence strength: Preclinical; Eudragit is a delivery vehicle in studies of anti-IBD compounds.
Probiotic supplementation represents a promising therapeutic strategy for microbiota modulation; specifically, Lactobacillus reuteri has been shown to improve microbial community structure and suppress colonization by pathogens. A hierarchically structured double-encapsulated probiotic system (AMS@Eud) integrates calcium alginate microspheres with a Eudragit® resin coating.
These formulations are evaluated in murine colitis models and in vitro colonic simulation systems. No clinical trials evaluating Eudragit-coated probiotic supplements specifically for IBD endpoints in human subjects have been identified in the reviewed literature.
Eudragit is listed in the USP/NF, British Pharmacopoeia (BP), European Pharmacopoeia (Ph.Eur.), and the Handbook of Pharmaceutical Excipients. This multi-pharmacopeial status reflects extensive regulatory review and acceptance as a pharmaceutical excipient. Eudragit® E PO (basic methacrylate copolymer) has also been submitted under the FDA's voluntary GRAS notification program, specifically for use in micronutrient and supplement applications, with GRAS dossier documentation covering residual monomers and solvents, general specifications and stability data, estimated daily intake from proposed uses, short-term and sub-chronic oral toxicity studies, and genotoxicity studies on the basic methacrylate copolymer.
Ingredients in the acrylates copolymer group all contain the monomers acrylic acid or methacrylic acid or one of their salts or esters. These ingredients are considered similar in that they are uniformly produced in chemical reactions that leave very little residual monomer. These very large polymers exhibit little toxicity.
Pharmacopeial monographs impose strict limits on residual monomers in Eudragit grades. For Eudragit E 12.5, the total monomers must be a maximum of 0.04%, tested according to the Ph.Eur., USP/NF, or JPE monograph. The polymer's high molecular weight (ranging from approximately 32,000 g/mol for RL grades to 280,000 g/mol for FS grades) means that it is not absorbed through the intestinal mucosa under normal conditions and passes through the GI tract essentially intact or dissolved into non-absorbable macromolecular fragments.
Some polymers have limitations, such as being non-compatible with active ingredients, non-biodegradable, and toxic; to overcome these problems, there is a growing concern for the synthesis of polymer by modern polymerization method with catalysis. This general observation about synthetic polymers applies to context-specific evaluations; however, Eudragit grades specifically have been subjected to extensive toxicological characterization over more than seven decades of use.
The free monomers from which Eudragit is synthesized—including methacrylic acid, methyl methacrylate, and ethyl acrylate—are individually reactive chemicals. Although residual acrylic acid may be as high as 1,500 ppm in acrylate copolymers generally, typical levels are 10 to 1,000 ppm. However, pharmacopeial quality Eudragit grades are subject to specific residual monomer limits (typically ≤0.04% for solid grades), and the polymer is extensively tested prior to use in pharmaceutical and supplement applications. The concern about free monomers is therefore substantially mitigated in compliant grades.
It should be noted that effects from ingestion of free methacrylic acid include drooling, gagging, and vomiting, and children exposed to methacrylic acid as a result of accidental spills have suffered first and second degree burns. This is relevant to the free acid, not to the polymerized copolymer in pharmacopeial grades, but underscores the importance of ensuring that Eudragit materials used in supplements meet pharmacopeial residual monomer specifications.
Cytotoxicity of the microparticles formulated with Eudragit polymers was evaluated (0.5–20 mg/mL) on Caco-2 cells, showing high cytocompatibility. Caco-2 cells are a standard model for human intestinal epithelial cells. This finding is consistent across multiple published in vitro studies.
Given the high molecular weight of Eudragit copolymers and their insolubility at gastric pH (for the anionic grades), they do not undergo significant absorption through the intestinal epithelium. Where they do dissolve (at intestinal pH), the resulting macromolecular fragments are not expected to be absorbed systemically. This is consistent with the long clinical use history of these polymers as pharmaceutical excipients. However, formal systemic pharmacokinetic studies of Eudragit polymers in humans have not been identified in the reviewed literature.
The glass transition temperature of Eudragit grades affects pharmaceutical dosage from storage conditions, film production, melt processing, etc. Small molecules of drugs, solvents, or plasticizers lower the glass transition temperature; these properties are important for pharmaceutical applications. The primary "interaction" of relevance is the potential for certain highly ionizable or reactive active ingredients to interact with the ionic groups of Eudragit at the molecular level during formulation, potentially reducing active ingredient stability or loading efficiency. Formulators must characterize compatibility between the chosen Eudragit grade and the active ingredient on a case-by-case basis.
No drug-excipient interactions in the sense of pharmacological in vivo interactions between Eudragit-derived polymer fragments and co-ingested therapeutics have been documented in the reviewed literature.
Health conditions that Eudragit may help support.
Body systems that Eudragit may help support.
Go back